This liposome could significantly increase the cytokine rations of IL-12/IL-4, IL12/IL-1α, IL-12/IL-1β, IFN-γ/IL-6, IFN-γ/IL-1α, and IFN-γ/IL-1β by 1.18–3.14-fold, (P < 0.05), thus favoring the balance of Th1 and Th2 cells to stimulate antitumor effects in the tumor microenvironment. The gene discussed is IL6; the disease is neoplasm.